Articles

< Previous         Next >  
Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells Free
Thomas Gruber1,†,*, Reinhard Hinterleitner1,†, Natascha Hermann-Kleiter1, Marlies Meisel1, Ingo Kleiter2, Chiuhui Mary Wang3, Antonella Viola3, Christa Pfeifhofer-Obermair1, and Gottfried Baier1
1Department for Pharmacology and Genetics, Medical University of Innsbruck, Innsbruck, Austria
2Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum, Germany
3Humanitas Clinical and Research Center, 20089 Rozzano (MI), Italy *Correspondence to:Thomas Gruber, E-mail: thomas.gruber@i-med.ac.at
J Mol Cell Biol, Volume 5, Issue 6, December 2013, 358-368,  https://doi.org/10.1093/jmcb/mjt017
Keyword: TGFβ signaling, Cbl-b, SMAD

T cell-intrinsic transforming growth factor β (TGFβ) receptor signaling plays an essential role in controlling immune responses. The RING-type E3 ligase Cbl-b has been shown to mediate the sensitivity of T cells to TGFβ; however, the mechanism underlying this process is unknown. This study shows that SMAD7, an established negative regulator of TGFβ receptor (TGFβR) signaling, is a key downstream effector target of Cbl-b. SMAD7 protein levels, but not SMAD7 mRNA levels, are upregulated in cblb−/− T cells. Cbl-b directly interacts with and ubiquitinates SMAD7, suggesting that Cbl-b posttranscriptionally regulates SMAD7. In support of this notion, concomitant genetic loss of SMAD7 in cblb−/− mice restored TGFβ sensitivity on T cell cytokine responses and abrogated the tumor rejection phenotype of cblb−/− mice. These results demonstrate an essential and non-redundant role for Cbl-b in controlling TGFβR signaling by directly targeting SMAD7 for degradation during T cell responses in vitro and in vivo.